Evotec stock edges higher after dermatology milestone with Almirall

Published on 09/02/2026 at 06:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock trades just above its recent low as investors weigh a new dermatology milestone with partner Almirall against earlier guidance cuts and weak five-year returns.

Schwarzweiß-Dokumentarfoto einer Forscherin am Mikroskop in einem biotechnologischen Labor — Schwarzweiß-Reportagefoto zeigt Laborarbeit im Biotech-Sektor, passend zu Evotec SE, ISIN DE0005664809, dokumentarischer Forschungsalltag, Illustration mit AI erstellt.

Evotec SE (ISIN DE0005664809) stock is trading only slightly above its recent low, while a new dermatology milestone with partner Almirall and weak five-year performance keep the biotech group in investors' sights as of September 1, 2026.

Stock hovers near 52-week low

According to a recent performance analysis on a German stock portal, Evotec shares closed at 3.25 EUR on August 31, 2026, marking the end-of-month price for the TecDAX-listed company on Xetra.

The same analysis shows that Evotec stock had been at 42.24 EUR five years earlier, implying a price decline of about 92.3 percent over that five-year period for long-term investors.

For investors, this steep drawdown means that even small positive catalysts now stand out more clearly in the trading pattern of Evotec stock.

Dermatology milestone with Almirall

A separate biotech news report highlights that Evotec and Spanish dermatology specialist Almirall have reached a preclinical development milestone in record time in their cooperation on immune-related inflammatory skin diseases.

According to the same report, Evotec and Almirall have identified a preclinical development candidate two years after the start of their collaboration, underscoring the pace at which Evotec's discovery platforms can deliver pipeline assets for partners.

For investors watching the stock, this milestone does not immediately change reported revenue or profit figures but adds optionality to Evotec's partnered pipeline, which can translate into potential milestone and royalty streams over the medium term.

Go deeper

More on Evotec stock and reports

For a broader view of Evotec's share performance and upcoming disclosures, the following links provide additional price data and investor information.

All Evotec news and prices Investor Relations

Pipeline and partnered products

Beyond its Almirall collaboration, Evotec also licenses assets to other biotech companies, such as EVT801, a small molecule inhibitor of VEGFR3 that was licensed to Kazia Therapeutics in April 2021 for development in oncology indications.

This licensing activity illustrates Evotec's business model of using its discovery and development platforms to generate partnered assets rather than relying solely on wholly owned products, offering a diversified revenue base from milestones and potential future royalties.

Price level and investor perspective

With Evotec shares around 3.25 EUR at the close on August 31, 2026 on Xetra, far below their 42.24 EUR level five years earlier, the stock continues to trade in the lower part of its multi-year range, reflecting both past guidance cuts and the market's cautious stance on the company's execution risk.